Literature DB >> 31996958

Extracorporeal liver support in patients with liver failure.

Xiaomei Xu1,2, Bo Qin3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 31996958     DOI： 10.1007/s00134-020-05928-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  6 in total

1.  [Clinical effect of combined artificial extracorporeal liver support therapy for toxic hepatic failure].

Authors:  Y D Zhou; L Yang; Q F Han; Q B Tang; Y L Cheng; J X Shi
Journal:  Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi       Date:  2017-01-20

2.  Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure.

Authors:  J G O'Grady; A E Gimson; C J O'Brien; A Pucknell; R D Hughes; R Williams
Journal:  Gastroenterology       Date:  1988-05       Impact factor: 22.682

3.  First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock.

Authors:  A El Banayosy; L Kizner; V Schueler; S Bergmeier; D Cobaugh; R Koerfer
Journal:  ASAIO J       Date:  2004 Jul-Aug       Impact factor: 2.872

4.  Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials.

Authors:  Fayez Alshamsi; Khalil Alshammari; Emilie Belley-Cote; Joanna Dionne; Talal Albrahim; Budoor Albudoor; Mona Ismail; Bandar Al-Judaibi; Bandar Baw; Ram M Subramanian; Randolph Steadman; Dragos Galusca; David T Huang; Rahul Nanchal; Mustafa Al Quraini; Yuhong Yuan; Waleed Alhazzani
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

5.  Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience.

Authors:  Gang Qin; Jian-Guo Shao; Bin Wang; Yi Shen; Jian Zheng; Xian-Jin Liu; You-Yi Zhang; Yan-Mei Liu; Yan Qin; Lu-Jun Wang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

6.  Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial.

Authors:  Julie Thompson; Natasha Jones; Ali Al-Khafaji; Shahid Malik; David Reich; Santiago Munoz; Ross MacNicholas; Tarek Hassanein; Lewis Teperman; Lance Stein; Andrés Duarte-Rojo; Raza Malik; Talal Adhami; Sumeet Asrani; Nikunj Shah; Paul Gaglio; Anupama Duddempudi; Brian Borg; Rajiv Jalan; Robert Brown; Heather Patton; Rohit Satoskar; Simona Rossi; Amay Parikh; Ahmed ElSharkawy; Parvez Mantry; Linda Sher; David Wolf; Marquis Hart; Charles Landis; Alan Wigg; Shahid Habib; Geoffrey McCaughan; Steven Colquhoun; Alyssa Henry; Patricia Bedard; Lee Landeen; Michael Millis; Robert Ashley; William Frank; Andrew Henry; Jan Stange; Ram Subramanian
Journal:  Liver Transpl       Date:  2018-03       Impact factor: 5.799
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.